← Back to Clinical Trials
Recruiting NCT07272473

NCT07272473 Effects of Cervical Mobilization on Dizziness, Balance, and Joint Position Sense in Patients With Meniere's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07272473
Status Recruiting
Phase
Sponsor Abant Izzet Baysal University
Condition Meniere Disease
Study Type INTERVENTIONAL
Enrollment 33 participants
Start Date 2025-09-20
Primary Completion 2026-03-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 60 Years
Study Type INTERVENTIONAL
Interventions
Vestibular Rehabilitation + Cervical Mobilizationvestibular rehabilitation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 33 participants in total. It began in 2025-09-20 with a primary completion date of 2026-03-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study will employ a stratified randomization method. Patients presenting to the Afyonkarahisar Health Sciences University Health Application and Research Center, Ear, Nose, and Throat Outpatient Clinic, with a definitive diagnosis of Meniere's disease, unilateral or bilateral involvement, and who consent to participate in the study will be divided into three groups. The control group will receive only their routine Betahistine. Their usual treatment will remain unchanged. The first study group will receive 20 minutes of Vestibular Rehabilitation (VR) and 10 minutes of cervical mobilization in addition to their routine Betahistine. The second study group will receive 30 minutes of VR in addition to Betahistine. The study will last 6 weeks. Participants will be assessed using a sociodemographic information questionnaire, the Dizziness Handicap Inventory (DHI), the Vertigo Symptom Scale (VSS), the Neck Disability Index (NDI), the International Tinnitus Inventory (ITI), balance assessment with the K-Force Plates, and joint position sense and proprioception assessment with the Kinvent Physio K-Move. All assessments will be conducted twice, before and after treatment.

Eligibility Criteria

Inclusion Criteria: * Definitive clinical diagnosis of unilateral or bilateral Meniere's disease * Age between 18 and 60 years * Presence of fluctuating symptoms or chronic imbalance for at least 3 months * Cognitive ability to participate in balance rehabilitation tasks (Mini Mental State Examination score ≥ 24) * Willingness to participate in the study and provide informed consent Exclusion Criteria: * Diagnosis of vertigo not associated with Meniere's disease * Presence of another acute medical condition * Neurological, psychological, or cognitive dysfunction * History of orthopedic surgery within the last 3 months * Planned surgical intervention during the rehabilitation program * Cervical spine instability * Acute cervical trauma * Vertebral artery insufficiency

Contact & Investigator

Central Contact

nurgul sarı, Master's Degree

✉ nurgulsen12@gmail.com

📞 +905344527440

Principal Investigator

omer pala, associate professor

STUDY DIRECTOR

Abant Izzet Baysal University

Frequently Asked Questions

Who can join the NCT07272473 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Meniere Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07272473 currently recruiting?

Yes, NCT07272473 is actively recruiting participants. Contact the research team at nurgulsen12@gmail.com for enrollment information.

Where is the NCT07272473 trial being conducted?

This trial is being conducted at Afyonkarahisar, Turkey (Türkiye).

Who is sponsoring the NCT07272473 clinical trial?

NCT07272473 is sponsored by Abant Izzet Baysal University. The principal investigator is omer pala, associate professor at Abant Izzet Baysal University. The trial plans to enroll 33 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology